Three new indications of pegylated recombinant human growth hormone injection in Jinsai pharmaceutical were approved

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without any false record, misleading statement or major omission The clinical trial application for adding three new indications of pegylated recombinant human growth hormone injection of Changchun Jinsai Pharmaceutical Co., Ltd (hereinafter referred to as "Jinsai pharmaceutical"), a holding subsidiary of Changchun high tech industry (Group) Co., Ltd (hereinafter referred to as "the company"), has been approved by the State Food and Drug Administration in 2014 On December 2, 2004, the approval document for clinical trials of drugs was received from Jilin food and drug administration According to the approval document for clinical trials of drugs issued by the State Food and drug administration, the indications approved for clinical trials include: Children's idiopathic short stature (ISS), adults' growth hormone deficiency (AGHD) and congenital ovarian dysgenesis (Turner) The registration classification is biological products for treatment According to the relevant provisions of the state, clinical trials shall be carried out within 3 years from the date of approval Jinsai pharmaceutical will complete the corresponding clinical trials according to the plan, and it is preliminarily expected to start the clinical trials in 2015 The specific completion time of all clinical trials cannot be determined temporarily The company will timely perform the information disclosure obligation for the follow-up progress of the project Please make careful decisions and pay attention to investment risks It is hereby announced Board of directors of Changchun high tech industry (Group) Co., Ltd December 4, 2014